Chad Brokaw
Patients with structural heart disease can take very different routes before reaching the heart team. It can be difficult to reduce variability in care across the hospital system for this large patient population.
Clinical trials are necessary to ensure the safety and efficacy of new therapies, but they can be time-consuming, costly and inefficient to enroll, slowing down access to lifesaving treatment options. The future of faster clinical trials is here.
Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation. First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona.
Study Led by John Mignone, M.D., Ph.D., Presented at the Heart Rhythm Society’s Annual Meeting. Key Findings Demonstrate Increased Survival for Patients Receiving Combined Device and 4-Class Medical Therapy.
© 2022 egnite, Inc. All Rights Reserved. egnite, egnite Inc., and the stylized logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.